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Background and Aims: Non-invasive fibrosis staging is essential in metabolic
associated fatty liver disease (MAFLD). Transient elastography (TE) is a well-established
method for liver fibrosis assessment. We have previously shown that the macrophage
marker sCD163 is an independent predictor for fibrosis in MAFLD. In the present
study we tested whether the combination of macrophage markers and TE improves
fibrosis prediction.
Methods: Wemeasured macrophage markers soluble (s)CD163 andmannose receptor
(sMR) in two independent cohorts from Italy (n = 141) and Sweden (n = 70) with
biopsy-proven MAFLD and available TE.
Results: In the Italian cohort, TE and sCD163 showed similar moderate associations
with liver fibrosis (rho = 0.56, p < 0.001 and rho = 0.42, p < 0.001, respectively). TE
had an area under the Receiver Operating Characteristics curve (AUROC, with 95% CI)
for fibrosis; F ≥ 2 = 0.79 (0.72–0.86), F ≥ 3 = 0.81 (0.73–0.89), F4 = 0.95 (0.90–1.0).
sCD163 also predicted fibrosis well [F ≥ 2= 0.71 (0.63–0.80), F ≥ 3= 0.82 (0.74–0.90),
F4= 0.89 (0.76–1.0)]. However, combining sCD163 and TE did not improve the AUROCs
significantly [F ≥ 2 = 0.79 (0.72–0.86), F ≥ 3 = 0.85 (0.78–0.92), F4 = 0.97 (0.93–1.0)].
In the Swedish cohort, TE showed a closer association with fibrosis (rho = 0.73,
p < 0.001) than sCD163 (rho = 0.43, p < 0.001) and sMR (rho = 0.46, p < 0.001). TE
predicted fibrosis well [F ≥ 2 = 0.88 (0.80–0.97), F ≥ 3 = 0.90 (0.83–0.97), F4 = 0.87
(0.78–0.96)], whereas sCD163 did not (best AUROC 0.75). sMR showed a better
prediction [F ≥ 2 = 0.68 (0.56–0.81), F ≥ 3 = 0.82 (0.71–0.92), F4 = 0.79 (0.66–0.93)],
but the addition of sMR did not further improve the prediction of fibrosis by TE.
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Conclusion: In these cohorts of MAFLD patients, TE was superior to macrophage
markers for fibrosis prediction and in contrast to our hypothesis the addition of these
markers to TE did not improve its predictive capability.
Keywords: macrophages, cirrhosis, biomarkers, NAFLD, Fibroscan
INTRODUCTION
Metabolic associated fatty liver disease (MAFLD), a newly
instituted and more appropriate term for non-alcoholic fatty
liver disease (NAFLD) (1), is an increasingly prevalent liver
condition estimated to affect a quarter of the world’s population
with even higher prevalence in the constantly growing group of
subjects with obesity and type 2 diabetes (2). The majority of
patients with MAFLD do not develop significant liver disease,
however, some of them may progress to cirrhosis and liver
failure ultimately warranting a liver transplant. In this respect, the
stage of fibrosis has repeatedly proved to be the most important
determinant of outcome in MAFLD patients (3, 4), making
accurate identification of patients with advanced fibrosis crucial
in the management of MAFLD. So far, liver biopsy remains
the gold standard for fibrosis staging in MAFLD, however it
is invasive and thus not suitable for general use given the
vast numbers of subjects in need of examination. Therefore, a
number of non-invasive tools for fibrosis assessment have been
established (5).
Transient elastography (TE) provides the value of liver
stiffness as a measure of fibrosis. It has shown good accuracy
in MAFLD, particularly for advanced fibrosis and cirrhosis
detection (6), and has been introduced into the practical
guidelines for MAFLD diagnosis and management (7). However,
TE has several limitations including imperfect prediction (8).
Therefore, combinations of TE with other markers have
been explored, for instance, a recent multi-center study
developed and validated a score consisting of TE, controlled
attenuation parameter (CAP) and aspartate aminotransferase
(AST) to identify MAFLD patients with inflammatory activity,
steatohepatitis and significant fibrosis (9).
Macrophages play an important role in MAFLD (10), and
we and others have shown good predictive capability of the
macrophage specific marker soluble (s)CD163 for fibrosis in
MAFLD (11, 12). Furthermore, the addition of sCD163 to
the established NAFLD fibrosis score (NFS) improved its
performance (13). Another macrophage marker, the soluble
mannose receptor (sMR), is associated with acute and chronic
liver disease (14–16) and has not been investigated in adult
MAFLD before.
We hypothesized that combining the macrophage markers
sCD163 or sMR with TE would result in improvement of fibrosis
prediction, and we tested this hypothesis in two independent
cohorts of MAFLD patients with biopsy-proven disease.
METHODS
Study Population
This cross-sectional study was performed in two established
cohorts of MAFLD patients from liver centers in Italy and
Sweden. The Italian cohort consisted of patients from the
Division of Gastroenterology and Hepatology, Department of
Medical Sciences, University of Torino, Italy, while the Swedish
cohort comprised patients included at the Karolinska University
Hospital, Stockholm, Sweden. Both of these cohorts have been
described in previously published reports (13, 17).
At both sites, all patients were referred for the investigation
of abnormal liver tests or steatosis detected by ultrasound, and
MAFLD was diagnosed by liver biopsy. In the Italian cohort,
all patients had an alcohol intake of <20 g/day assessed by
interviews with the patient or close family members, and in
the Swedish cohort an intake of <30 g/day (males) an <20
g/day (females), assessed with phosphatidylethanol (PEth) and
the alcohol-use disorders identification test (AUDIT) and the
lifetime drinking history (LDH) questionnaires (18, 19).
Liver disease of other etiology was excluded. The number
of patients with biopsy-proven MAFLD and available TE was
141 in the Italian cohort and 70 in the Swedish cohort. At
the time of liver biopsy, demographic and clinical data were
recorded, including age, gender, ethnicity, height, weight, and
waist circumference. Body Mass Index (BMI) was calculated.
Diabetes was defined as hemoglobin A1c≥ 48 mmol/mol, fasting
blood glucose≥7.0 mmol/L, previous diagnosis of diabetes or use
of anti-diabetic drugs.
At the time of biopsy, a fasting blood sample was obtained
and routine biochemical tests were performed. Additional blood
samples were drawn and frozen at −80◦C for future research.
All patients signed an informed consent form in accordance
with the Helsinki Declaration. The acquisition, storage, and use
of blood samples were approved by the Ethics Committee of
the University Hospital San Giovanni Battista of Torino and
by the Regional Ethics Committee of Stockholm (2011/13-31-/1
and 2018/134-32).
Biochemical Analyses
Liver and hematological parameters, fasting glucose and
insulin, triglycerides and cholesterol and its components were
determined using standard assays and methods. All sCD163
and sMR measurements were performed at the Department of
Clinical Biochemistry, Aarhus University Hospital.
This was done in duplicate by in-house enzyme-linked
immunosorbent assays (ELISAs) using a BEP-2000 ELISA-
analyzer (Dade Behring) essentially as previously described (20,
21). Soluble CD163 and sMR are both resistant to repeated
freezing and thawing (20–22). Control samples and serum
standards were included in each run to avoid bias. We have
previously established reference intervals for sCD163 (0.69–3.86
mg/L) and sMR (0.10–0.43 mg/L) in large cohorts of healthy
individuals using the same assays (21, 23).
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Histological Analysis
Liver biopsies were stained and examined locally by experienced
pathologists as described by Kleiner et al. (24) and in accordance
with the Fatty Liver Inhibition of Progression (FLIP) algorithm
for the diagnosis of steatohepatitis (25). All biopsies had
a minimum of 11 portal tracts, and inadequate biopsies
were excluded.
Transient Elastography
Vibration controlled transient elastography (FibroScan,
Echosens, Paris, France) was performed within 2 weeks prior
to the liver biopsy by expert operators in accordance with the
instructions by the manufacturing company, including at least
3 h of fasting. The M probe was used as standard, and the XL
probe as per the automatic probe selection tool or when the M
probe failed.
TE was expressed in kilopascal (kPa) and calculated as the
median value of 10 successful acquisitions, defined by a success
rate of >60%, and by an interquartile range <30%.
Calculation of the NAFLD Fibrosis Score
and FIB-4
The NFS was calculated using the existing formula: −1.675 +
0.037 × age (years) + 0.094 × body mass index (kg/m2) + 1.13
× impaired glucose tolerance/diabetes mellitus (yes = 1, no =
0)+ 0.99× aspartate aminotransferase/alanine aminotransferase
– 0.013 × platelets (x109/L) – 0.66 × albumin (g/dL) (26). The
FIB-4 was calculated using the following formula: age (years)
× aspartate aminotransferase(U/L)/[platelets (x109/L) × square
root (alanine aminotransferase(U/L))] (27).
Statistical Methods
Student’s t-test was used for the comparison of normally
distributed variables between the groups. For non-normally
distributed data, the Mann-Whitney test was used. The
relationship between sCD163/sMR and TE was analyzed by
linear regression. Spearman’s rank test was used to study the
relationships of TE, sCD163, and sMR with histological scores.
For differences in proportions, we used the χ2-test or Fisher’s
exact test.
Multiple ordered logistic regression was used to assess the
relationship between the histological fibrosis score and TE,
sCD163, and sMR. This analysis provides odds ratios (OR)
describing the increase in the odds for a given fibrosis stage in a
patient who has a specific increase in a parameter compared with
another patient. We chose to present the results corresponding
to a 25% increase in TE, sCD163 and sMR based on our previous
experience (13, 28) and the distribution of these parameters
according to fibrosis stages. We used multiple logistic regression
analysis with given fibrosis stages (separate analysis for F ≥
2, F ≥ 3, F4 stages) as the dependent variable and TE and
sCD163/sMR as the explanatory to identify the best fittingmodels
for predicting a given fibrosis stage, separately for the Italian
and the Swedish cohort. The coefficients from this analysis were
used as relative weights to compute the respective combined
models. We then used the non-parametric Receiver Operating
Characteristics (ROC) analysis to assess the performance of
TE, sCD163/sMR, and their combinations in the prediction
of fibrosis stages, followed by tests of equality of areas under
the ROC curve (AUROCs) to compare the performance of
individual markers and composite models. All data are expressed
as means ± SD and medians with interquartile ranges (IQR) or
proportions. A p ≤ 0.05 was considered statistically significant.
STATA version 14.0 R©StataCorp LP was used for data analysis.
RESULTS
Patients Characteristics
Demographic, clinical, biochemical, and histological data for the
patients from both cohorts are shown in Table 1. The patients
in the Swedish cohort were older, and a higher proportion had
diabetes. Likewise, the Swedish patients had histologically more
severe MAFLD, with more frequent steatohepatitis and advanced
fibrosis stages. In addition, the levels of sCD163 and AST were
also higher in the patients from the Swedish cohort.
Associations of Macrophage Markers and
TE With Fibrosis
In the Italian cohort, sCD163 showed a moderate association
with fibrosis (rho = 0.42, p < 0.001), as shown in Figure 1A.
TE also correlated well with fibrosis (rho = 0.56, p < 0.001;
Figure 1B). TE showed an even closer association with fibrosis
in the Swedish cohort (rho = 0.73, p < 0.001; Figure 1B), which
was better than for sCD163 (rho = 0.43, p < 0.001; Figure 1A),
and sMR (rho= 0.46, p < 0.001; Figure 1C).
In the multiple ordered logistic regression analysis, both
TE and sCD163 were significantly associated with the stage of
fibrosis (OR = 1.05, p < 0.001 and OR = 1.13, p = 0.013,
respectively) in the Italian cohort. In the same analysis including
TE and sCD163 in patients from Sweden, TE showed a significant
association (OR = 1.03, p = 0.002) and sCD163 showed a trend
(OR = 1.05, p = 0.088). Similarly, the multivariate analysis with
TE and sMR as the explanatory variables resulted in a significant
association by TE (OR= 1.03, p= 0.004) and a trend by sMR (OR
= 2.38, p = 0.062). When including both TE, sCD163, and sMR
in the analysis in the Swedish cohort, TE remained significantly
associated with fibrosis (OR= 1.03, p= 0.006), whereas sCD163
and sMR lost significance (OR= 1.03, p= 0.32 and OR= 1.91, p
= 0.21, respectively).
Prediction of Fibrosis by TE, Macrophage
Markers, and Combined Models
In the ROC analysis, both TE and sCD163 showed good
prediction of fibrosis in the Italian cohort, especially for F≥ 3 and
F4 stages. Combining TE and sCD163 resulted in slightly higher
AUROCs than for TE alone, however, this improvement was not
statistically significant (Table 2).
Nevertheless, we explored whether the numerically higher
AUROC of the combined model translated into an improvement
in the negative and positive predictive values (NPV and PPV).
We thus determined the predictive characteristics of TE and the
combined model (TE + sCD163) for advanced fibrosis (F ≥ 3)
based on its importance for long-term outcome in MAFLD (4).
We used the established cut-off values for TE (<7.9 and ≥9.6
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TABLE 1 | Patient characteristics.
Italian cohort Swedish cohort P
(n = 141) (n = 70)
Age (years) 43 ± 11 51 ± 14 <0.001
Sex [m/f (%)] 106 (75%)/35 (25%) 48 (69%)/22 (31%) 0.31
BMI (kg/m2 ) 28 ± 4 31 ± 4 <0.001
Diabetes [n (%)] 34 (24%) 19 (35%) 0.02
Steatohepatitis (FLIP algorithm) [n (%)] 78 (55%) 49 (70%) 0.04
Fibrosis stage [n (%)]
0 50 (35%) 9 (13%) <0.001
1 29 (21%) 26 (37%)
2 30 (21%) 14 (20%)
3 25 (18%) 8 (11%)
4 7 (5%) 13 (19%)
F ≥2, NAS ≥4 and steatohepatitis [n (%)] 31 (22%) 25 (36%) 0.03
sCD163 (mg/L) 1.6 (1.2–2.3) 3.4 (2.3–4.8) <0.001
sMR (mg/L) - 0.28 (0.22–0.39) -
ALT (IU/L) 66 (42–94) 68 (47–114) 0.23
AST (IU/L) 36 (28–48) 47 (34–68) <0.001
Albumin (g/L) 46 ± 4 39 ± 3 <0.001
Platelets (x109/L) 230 ± 70 216 ± 57 0.16
Parameters are presented asmeans±SD for normally distributed andmedians (interquartile range) for non-normally distributed variables, and as total number (%) for categorical variables.
BMI, Body Mass Index; FLIP, Fatty Liver Inhibition of Progression; sCD163, soluble CD163; sMR, soluble mannose receptor; ALT, alanine transaminase; AST, aspartate transaminase.
kPa) (29), and determined 2 cut-offs values of the combined
model, a low cut-off for ruling out and a high cut-off for ruling
in advanced fibrosis, based on the ROC curve (Figure 2). The
combined model showed slightly higher NPV (92 vs. 88%) and
PPV (62 vs. 50%) (Table 3).
In the Swedish cohort, the AUROCs of sCD163 and sMR were
moderately good, whereas TE performed even better. Adding
sCD163, sMR or both of these markers to TE failed to change
its AUROCs (Table 2), for which reason we did not pursue the
predictive values of the combined models.
Prediction of Combined Significant Activity
and Fibrosis
Besides fibrosis, the presence of necroinflammatory activity
and steatohepatitis may be determinants of progressive disease
and pharmacological response, and a combination of at least
significant (≥F2) fibrosis, steatohepatitis and NAFLD activity
score (NAS)≥4 has been proposed to identify patients at risk and
inclusion into clinical trials (9). In the Italian cohort, 22 percent
of the patients had a combination of these features, and 36
percent in the Swedish cohort (Table 1). We tested the ability of
macrophage markers and TE to predict this composite endpoint.
Neither sCD163 nor sMR performed well, with AUROCs below
0.70. TE showed better prediction, but still with AUROCs lower
than 0.80 in both cohorts (Table 4). Combining the parameters
did not improve the AUROCs (Table 4). AST, which was included
in the composite score in the report mentioned above (9), showed
AUROCs similar to those of sCD163 (highest AUROC 0.69),
and the addition of AST to TE did not improve its performance
(highest AUROC 0.77).
Of note, sCD163 was not significantly higher in the patients
with NASH [1.69 (1.19–2.4) vs. 1.52 (1.15–2.24) mg/L, p =
0.43] in the Italian cohort. In the Swedish cohort, this was
the case for both sCD163 [3.59 (2.35–4.94) vs. 2.97 (1.97–4.61)
mg/L, p = 0.31] and sMR [0.29 (0.24–0.39) vs. 0.25 (0.22–0.32)
mg/L, p = 0.42]. Furthermore, looking at the histological grades
of steatosis, lobular inflammation and hepatocyte ballooning,
sCD163 was only significantly associated with steatosis in the
Italian cohort, whereas sMR tended to associate with ballooning
in the Swedish cohort. TE showed no significant correlation
with any histological measures other than fibrosis in any cohort
(Supplementary Tables 1, 2).
Macrophage Markers in Relation to NAFLD
Fibrosis Score and FIB-4
We calculated the established markers of liver fibrosis NAFLD
Fibrosis Score and FIB-4 in both cohorts. In the Italian cohort,
FIB-4 and NFS had higher AUROCs for F ≥ 2 compared with
sCD163, whereas sCD163 had higher AUROCs for F ≥ 3 and
F4 stages (Table 5). A combination of sCD163 and NFS resulted
in an AUROC higher than both of these markers alone for F
≥ 2 fibrosis, and combinations of sCD163 with FIB-4 and NFS
showed slightly higher AUROCS for F ≥ 3. The other possible
combinations did not result in increasing AUROCs (Table 5).
In the Swedish cohort, FIB-4 had higher AUROCs than both
sCD163 and sMR for all fibrosis stages. Combining FIB-4 with
sMR provided higher AUROCs for F ≥ 2 and F ≥ 3 stages than
both these markers, whereas combinations with sCD163 did not
result in additional predictive value.
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FIGURE 1 | Associations of macrophage markers and transient elastography
with fibrosis in the two cohorts. (A) sCD163 in the Italian and Swedish cohorts.
Italian cohort, rho = 0.42, p < 0.001; Swedish cohort, rho = 0.43, p < 0.001.
(B) TE in the Italian cohort and Swedish cohorts. Italian cohort, rho = 0.56, p
< 001; Swedish cohort, rho = 0.73, p < 0.001. (C) sMR in the Swedish
cohort, rho = 0.46, p < 0.001. Boxes represent interquartile ranges (IQR) with
medians; whiskers show adjacent values. sCD163, soluble CD163; TE,
transient elastography; sMR, soluble mannose receptor.
NFS showed moderate prediction for fibrosis in the Swedish
cohort, however, a combination of sCD163 and NFS had
an AUROC for F ≥ 2 higher than both these markers
alone (Table 5).
DISCUSSION
In this study of two independent cohorts of patients with biopsy-
proven MAFLD and available TE, we measured macrophage
markers sCD163 and sMR and combined them with TE
hypothesizing that this would improve the prediction of fibrosis.
The markers independently predicted fibrosis moderately well,
but in contrast to our hypothesis, adding sCD163 and sMR to
TE did not significantly improve its predictive capability.
Our study has strengths and limitations. The key strength
was the well-characterized patients with histologically classified
disease in two independent cohorts. Robust well-established and
validated methods including the XL probe were used for the
measurement of liver stiffness and for macrophage markers. The
most significant limitation was the lower number of patients
in the Swedish cohort, which inherently could raise the issue
of inadequate power, however, as the combinations of TE with
macrophage markers had generally lower AUROCs than TE
alone, we do not believe that a larger number of patients in
this cohort would have resulted in a better performance of the
combined models. A more general drawback may be the cross-
sectional design of the study and its focus on liver histology. Liver
biopsy is an imperfect gold standard due to potential sampling
error and interobserver variability, and the possible resulting bias
is not easily predictable.
Combinations of elastography with biochemical markers and
composite scores have been explored in MAFLD before. Gaia
et al. showed no improvement in the fibrosis prediction of TE
with the addition of ultrasonographic and biochemical measures
in a smaller study (30). A larger study of MAFLD patients
showed similar AUROCs for the FibroMeterTM-TE combination
and TE alone, however, with a markedly better PPV (31),
followed by a more recent study demonstrating higher AUROCs
for all fibrosis stages for the FibroMeterTM-TE model (32).
Similarly, another commercially available score, the Enhanced
Liver Fibrosis (ELFTM)-test, showed improved prediction when
combinedwith TE (33). The readily available and highly validated
models NAFLD fibrosis score (NFS) and FIB-4 have been
investigated in sequential algorithms with TE resulting in the
increase of correctly classified MAFLD patients (34–36).
In our study, sCD163 and sMR predicted fibrosis with
moderate accuracy. Furthermore, both sCD163 and sMR showed
independent associations with fibrosis in the multiple ordered
logistic regression analysis with TE as a covariate. These findings
supported our hypothesis and held promise of an add-on
value of the macrophage markers for fibrosis prediction when
combined with TE. Of note, in the Italian cohort the combination
of sCD163 and TE did in fact result in numerically higher
AUROCs than TE alone, as well as higher NPV and PPV for
advanced fibrosis. However, the increase in the AUROCs was not
significant and while the NPV of the combined model was strong
at 92%, TE in itself already had an adequate NPV at 88%. At the
same time, the PPV of the combinedmodel remained low at 62%,
a value not fit to rule in advanced fibrosis. In the Swedish cohort,
the AUROCs of the combined models were even slightly lower
compared to TE. Thus, based on our data, sCD163 and sMR did
not contribute to the detection of advanced fibrosis beyond TE.
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TABLE 2 | Areas under the Receiver Operating Characteristics curve with 95% Confidence Intervals for fibrosis stages prediction by sCD163, sMR and transient
elastography in the Italian and Swedish cohorts.
F ≥ 2 F ≥ 3 F4
Italian cohort
sCD163 0.71 (0.63–0.80) 0.82 (0.74–0.90) 0.89 (0.76–1.0)
TE 0.79 (0.72–0.87) 0.81 (0.73 – 0.89) 0.95 (0.90–1.0)
TE + sCD163 0.79 (0.72–0.86) 0.85 (0.78–0.92) 0.97 (0.93–1.0)
Swedish cohort
sCD163 0.70 (0.56–0.82) 0.75 (0.62–0.88) 0.75 (0.62–0.89)
sMR 0.68 (0.56–0.81) 0.82 (0.71–0.92) 0.79 (0.66–0.93)
TE 0.88 (0.80–0.97) 0.90 (0.83–0.97) 0.87 (0.78–0.96)
TE + sCD163 0.87 (0.78–0.96) 0.90 (0.83–0.96) 0.86 (0.76–0.95)
TE + sMR 0.88 (0.79–0.96) 0.89 (0.81–0.97) 0.85 (0.74–0.95)
TE + sCD163 + sMR 0.87 (0.78–0.96) 0.89 (0.82–0.97) 0.84 (0.74–0.95)
sCD163, soluble CD163; TE, transient elastography; sMR, soluble mannose receptor.
FIGURE 2 | Receiver Operating Characteristics curves for transient elastography and combined transient elastography + sCD163 for advanced fibrosis (F ≥ 3) in the
Italian cohort. Area under the ROC curve for transient elastography (TE) 0.81 (95% CI: 0.73–0.89), for the combined model 0.85 (95% CI: 0.78–0.92). The squares
show the high (H) (9.6 kPa) and low (L) (7.9 kPa) cut-off values for TE, and the circles the high (3.72) and low (2.93) cut-off values for the combined model.
Several explanations for this result can be considered. In
line with earlier studies, combining sCD163 and TE led to a
higher PPV in the Italian cohort, which however was too low for
practical use. This may partly be explained by the distribution
of fibrosis in the Italian cohort with only 23% having fibrosis
stage 3 or higher. The prevalence of disease affects predictive
values, and in this case, favors NPV over PPV. Thus, sCD163
may have had a more pronounced impact on PPV in a cohort
with more frequent advanced fibrosis. However, the distribution
of fibrosis stages does not explain the similar AUROCs of TE and
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TABLE 3 | Predictive value of transient elastography and combined transient elastography + sCD163 for advanced fibrosis (F ≥ 3) in the Italian cohort.
TE Low cut-off Indeterminable High cut-off Total
(<7.9 kPa) (7.9–9.6 kPa) (≥9.6 kPa)
Total 92 19 30 141
F 0–2 81 13 15 109
F 3–4 11 6 15 32
Sensitivity 66% 47%
Specificity 74% 86%
Positive predictive value 43% 50%
Negative predictive value 88% 85%
TE + sCD163 Low cut-off Indeterminable High cut-off Total
(≤2.93) (2.93–3.46) (≥3.72)
Total 75 34 32 141
F 0–2 69 28 12 109
F 3–4 6 6 20 32
Sensitivity 82% 62%
Specificity 63% 89%
Positive predictive value 41% 62%
Negative predictive value 92% 89%
sCD163, soluble CD163; TE, transient elastography.
TABLE 4 | Areas under the Receiver Operating Characteristics curve with 95%
Confidence Intervals for the prediction of combined fibrosis ≥2, NAFLD activity
score ≥4 and steatohepatitis by sCD163, sMR, AST and transient elastography in









TE + sCD163 0.75 (0.64–0.87)
TE + sMR 0.74 (0.62–0.85)
TE + sCD163 + sMR 0.76 (0.65–0.87)
sCD163, soluble CD163; TE, transient elastography; sMR, soluble mannose receptor.
combined models in the patients from the Swedish cohort, as
they had more severe fibrosis. The lack of an improvement of TE
prediction by addition of sCD163 and sMR may be rooted in the
nature of these biomarkers. sCD163 and sMRwere not developed
with the purpose of fibrosis detection, but are functional markers
of macrophage activation, and have been associated with liver
fibrosis reflecting the roles of macrophages in liver disease and
fibrogenesis (10). In contrast, the method of TE to determine
liver stiffness was identified and refined as a dedicated test of
liver fibrosis, as were composite scores such as the NFS (26), the
FibroMeterTM (37), and the ELFTM (38), which may explain that
these markers may have a higher usability than the macrophage
markers in terms of predictive values even with similar AUROCs.
In this regard, it may prove fruitful to examine combinations of
TE with other specific fibrosis markers, for instance the markers
of collagen turnover that also have shown promising results in
MAFLD (39).
Both sCD163 and sMR failed to help detect the combination
of significant fibrosis, steatohepatitis and necroinflammation
suggested as the FAST algorithm to identify patients with
progressive disease suitable for clinical trials (9), and the levels
of the macrophage markers were not significantly elevated in
patients with steatohepatitis. In some of the other cohorts
of MAFLD patients investigated by our group and others,
sCD163 was higher in subjects with steatohepatitis, however,
the association with fibrosis was considerably stronger (11–
13). We have previously explained this finding by the higher
variability in the histological assessment of features such as
steatosis and inflammation compared to fibrosis (24), as well as
by the dynamic nature of necroinflammatory activity, whereas
fibrosis remains more stable over time. It is therefore not to
be expected that macrophage markers can contribute to the
detection of inflammatory activity in MAFLD. However, it is
important to mention that the FAST algorithm will miss patients
with advanced fibrosis but no steatohepatitis, whose prognosis
is very similar to those who have both advanced fibrosis and
steatohepatitis (4, 40), for which reason the detection of fibrosis
is more appropriate for clinical practice.
In our study, the AUROCs of sCD163 were higher compared
with NFS and FIB-4 in the Italian cohort, whereas FIB-4 was
superior to sCD163 and sMR in the Swedish cohort. Interestingly,
in several instances the combinations of the macrophage markers
with NFS/FIB-4 showed AUROC values higher than the single
markers, which suggests that sCD163 and sMR may be valuable
as add-ons to the biomarker-based screening of MAFLD patients
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TABLE 5 | Areas under the Receiver Operating Characteristics curve with 95% Confidence Intervals for fibrosis stages prediction by sCD163, sMR, NAFLD Fibrosis Score
and FIB-4 the Italian and Swedish cohorts.
F ≥ 2 F ≥ 3 F4
Italian cohort
sCD163 0.71 (0.63–0.80) 0.82 (0.74–0.90)* 0.89 (0.76–1.0)
NFS 0.76 (0.68–0.85) 0.70 (0.59–0.81) 0.74 (0.40–1.0)
FIB-4 0.73 (0.65–0.82) 0.68 (0.57–0.79) 0.74 (0.44–1.0)
sCD163 + NFS 0.80 (0.72–0.88)‡ 0.83 (0.74–0.91)
†
0.81 (0.57–1.00)
sCD163 + FIB-4 0.76 (0.68–0.84) 0.83 (0.74–0.91)* 0.86 (0.69–1.00)
Swedish cohort
sCD163 0.70 (0.56–0.82) 0.75 (0.62–0.88) 0.75 (0.62–0.89)
sMR 0.68 (0.56–0.81) 0.82 (0.71–0.92) 0.79 (0.66–0.93)
NFS 0.64 (0.49–0.79) 0.75 (0.61–0.89) 0.87 (0.76–0.94)
FIB-4 0.74 (0.61–0.86) 0.85 (0.76–0.95) 0.92 (0.85–0.99)‡
sCD163 + NFS 0.66 (0.52–0.81) 0.81 (0.68–0.94) 0.88 (0.78–0.98)
sCD163 + FIB-4 0.76 (0.64–0.87) 0.86 (0.76–0.96)‡ 0.91 (0.83–0.98)‡
sMR + NFS 0.63 (0.48–0.78) 0.79 (0.67–0.91) 0.87 (0.77–0.97)
sMR+ FIB-4 0.76 (0.64–0.87) 0.89 (0.82–0.97) 0.92 (0.85–0.99)§
Combinations with possible synergy between markers in bold.
sCD163, soluble CD163; NFS, NAFLD Fibrosis Score; sMR, soluble mannose receptor.
*p < 0.05 compared with FIB-4.
†
p < 0.05 compared with NFS.
‡
p < 0.005 compared with sCD163.
§p < 0.05 compared with sMR.
in the setting of primary care. However, this should be further
tested in primary care cohorts more suitable for this purpose due
to the expectedly lower prevalence of advanced fibrosis compared
with our cohorts of patients referred to tertiary centers.
In conclusion, despite significant independent associations
with fibrosis in two cohorts of patient with MAFLD, macrophage
markers sCD163 and sMR did not improve the prediction of
fibrosis by TE in combined models. This may be attributed to the
nature of these markers as related to macrophage activation and
not fibrosis per se, and other more fibrosis specific markers may
be more useful and could be explored in future studies.
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